Cancer Statistics Registrations. Registrations of cancer diagnosed in 2001, England. London: Office for National Statistics, HMSO. ISSN 0143-4829, ISBN 1 85774 587 6.

Stratton, J. F., Pharoah, P. D. P., Smith, S. K., et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998), 105:493–9.CrossRefGoogle ScholarPubMed

Auranen, A., Pukkala, E., Makinen, J., et al. Cancer incidence in the first-degree relatives of ovarian cancer patients. Br J Cancer (1996), 74:280–4.CrossRefGoogle ScholarPubMed

Easton, D. F., Matthews, F. E., Ford, D., et al. Cancer mortality in relatives of women with ovarian cancer: the OPCS study. Int J Cancer (1996), 65:284–94.3.0.CO;2-W>CrossRefGoogle ScholarPubMed

Schildkraut, J. M. and Thompson, W. D.. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol (1988), 128:456–66.CrossRefGoogle ScholarPubMed

Sutcliffe, S., Pharoah, P. D., Easton, D. F., et al. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. Int J Cancer (2000), 87:110–7.3.0.CO;2-6>CrossRefGoogle ScholarPubMed

Lichtenstein, P., Holm, N. V., Verkasalo, P. K., et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000), 343:78–85.CrossRefGoogle Scholar

Houlston, R. S., Collins, A., Slack, J., et al. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet (1991), 55:291–9.CrossRefGoogle ScholarPubMed

Auranen, A. and Iselius, L.. Segregation analysis of epithelial ovarian cancer in Finland. Br J Cancer (1998), 77:1537–41.CrossRefGoogle ScholarPubMed

Miki, Y., Swensen, J., Shattuck-Eidens, D., et al. A strong candidate for the 17 linked breast and ovarian cancer susceptibility geneBRCA1. Science (1994), 266:66–71.CrossRefGoogle ScholarPubMed

Futreal, P. A., Liu, Q., Shattuck-Eidens, D., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994), 266:120–2.CrossRefGoogle ScholarPubMed

Wooster, R., Bignell, G., Lancaster, J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature (1995), 378:789–92.CrossRefGoogle ScholarPubMed

Gayther, S. A., Russell, P., Harrington, P., et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet (1999), 65:1021–9.CrossRefGoogle ScholarPubMed

Matsushima, M., Kobayashi, K., Emi, M., et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet (1995), 4:1953–6.CrossRefGoogle ScholarPubMed

Stratton, J. F., Gayther, S. A., Russell, P., et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med (1997), 336:1125–30.CrossRefGoogle ScholarPubMed

Rubin, S. C., Blackwood, M. A., Bandera, C., et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol (1998), 178:670–7.CrossRefGoogle Scholar

Janezic, S. A., Ziogas, A., Krumroy, L. M., et al. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet (1999), 8:889–97.CrossRefGoogle Scholar

Risch, H. A., McLaughlin, J. R., Cole, D. E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001), 68:700–10.CrossRefGoogle Scholar

Ford, D., Easton, D. F., Bishop, D. T., et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994), 343:692–5.CrossRefGoogle ScholarPubMed

Whittemore, A. S., Gong, G. and Itnyre, J.. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet (1997), 60:496–504.Google ScholarPubMed

Struewing, J. P., Hartge, P., Wacholder, S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997), 336:1401–8.CrossRefGoogle ScholarPubMed

Ford, D., Easton, D. F., Stratton, M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998), 62:676–89.CrossRefGoogle ScholarPubMed

Rubin, S. C., Benjamin, I., Behbakht, K., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996), 335:1413–6.CrossRefGoogle ScholarPubMed

Boyd, J., Sonoda, Y., Federici, M. G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000), 283:2260–5.CrossRefGoogle ScholarPubMed

Johannsson, O. T., Ranstam, J., Borg, A., et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol (1998), 16:398–404.CrossRefGoogle ScholarPubMed

Pharoah, P. D., Easton, D. F., Stockton, D. L., et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999), 59:868–71.Google ScholarPubMed

Aarnio, M., Mecklin, J. P., Aaltonen, L. A., et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer (1995), 64:430–3.CrossRefGoogle ScholarPubMed

Wheeler, J. M., Bodmer, W. F. and Mortensen, N. J.. DNA mismatch repair genes and colorectal cancer. Gut (2000), 47:148–53.CrossRefGoogle ScholarPubMed

Aarnio, M., Sankila, R., Pukkala, E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999), 81:214–18.3.0.CO;2-L>CrossRefGoogle ScholarPubMed

Lowe, S. M., Coughlan, S. J., McKenna, N. J., et al. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res (1995), 55:2743–5.Google Scholar

Spurdle, A. B., Webb, P. M., Purdie, D. M., et al. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis (2001), 22:717–21.CrossRefGoogle ScholarPubMed

Lancaster, J. M., Berchuck, A., Carney, M. E., et al. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. Br J Cancer (1998), 78:277.CrossRefGoogle ScholarPubMed

Pearce, C. L., Hirschhorn, J. N., Wu, A. H., et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst (2005), 97:51–9.CrossRefGoogle ScholarPubMed

Berchuck, A., Schildkraut, J. M., Wenham, R. M., et al. Progesterone receptor promoter +331A polymorphism is associated with increased risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev (2004), 13:2141–74.Google ScholarPubMed

Spurdle, A. B., Webb, P. M., Chen, X., et al. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int J Cancer (2000), 87:637–43.3.0.CO;2-R>CrossRefGoogle ScholarPubMed

Levine, D. A. and Boyd, J.. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res (2001), 61:908–11.Google ScholarPubMed

Garner, E. I., Stokes, E. E., Berkowitz, R. S., et al. Polymorphisms of the estrogen metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res (2002), 62:3058–62.Google ScholarPubMed

Spurdle, A. B., Chen, X., Abbazadegan, M., et al. CYP17 promotor polymorphism and ovarian cancer risk. Int J Cancer (2000), 86:436–9.3.0.CO;2-A>CrossRefGoogle ScholarPubMed

Runnebaum, I. B., Tong, X. W., Konig, R., et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet (1995), 345:994.CrossRefGoogle ScholarPubMed

Lancaster, J. M., Brownlee, H. A., Wiseman, R. W., et al. p53 polymorphism in ovarian and bladder cancer. Lancet (1995), 346:182.CrossRefGoogle ScholarPubMed

Fuller, R. E., Sood, A., Fullenkamp, C., et al. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther (1997), 4:239–45.Google Scholar

Spurdle, A. B., Purdie, D., Chen, X., et al. The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer. Cancer Res (2003), 90:145–9.Google Scholar

Lancaster, J. M., Taylor, J. A., Brownlee, H. A., et al. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog (1996), 17:160–2.3.0.CO;2-J>CrossRefGoogle ScholarPubMed

Spurdle, A. B., Purdie, D. M., Webb, P. M., et al. The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. Mol Carcinog (2001), 30:71–8.3.0.CO;2-9>CrossRefGoogle ScholarPubMed

Hengstler, J. G., Kett, A., Arand, M., et al. Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Lett (1998), 130:43–8.CrossRefGoogle ScholarPubMed

Spurdle, A. B., Webb, P. M., Purdie, D. M., et al. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis (2001), 22:67–72.CrossRefGoogle ScholarPubMed

Heitzel, J. N., Ding, S., Larson, G. P., et al. The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res (2000), 60:259–61.Google Scholar

Cramer, D. W., Hutchison, G. B., Welch, W. R., et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst (1983), 71:711–6.Google Scholar

Riman, T., Dickman, P. W., Nilsson, S., et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol (2002), 156:363–73.CrossRefGoogle ScholarPubMed

Whittemore, A. S., Harris, R. and Itnyre, J.. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol (1992), 136:1184–203.CrossRefGoogle ScholarPubMed

Purdie, D., Green, A., Bain, C., et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer (1995), 62:678–84.CrossRefGoogle ScholarPubMed

Polychronopoulou, A., Tzonou, A., Hsieh, C. C., et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer (1993), 55:402–7.CrossRefGoogle ScholarPubMed

Booth, M., Beral, V. and Smith, P.. Risk factors for ovarian cancer: a case-control study. Br J Cancer (1989), 60:592–8.CrossRefGoogle ScholarPubMed

Hankinson, S. E., Colditz, G. A., Hunter, D. J., et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer (1995), 76:284–90.3.0.CO;2-5>CrossRefGoogle ScholarPubMed

Adami, H. O.., Hsieh, C. C., Lambe, M., et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet (1994), 344:1250–4.CrossRefGoogle ScholarPubMed

Risch, H. A., Marrett, L. D. and Howe, G. R.. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol (1994), 140:585–97.CrossRefGoogle ScholarPubMed

Mosgaard, B. J., Lidegaard, O., Kjaer, S. K., et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril (1997), 67:1005–12.CrossRefGoogle ScholarPubMed

Gwinn, M. L., Lee, N. C., Rhodes, P. H., et al. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol (1990), 43:559–68.CrossRefGoogle ScholarPubMed

The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med (1987), 316:650–5.

Rosenberg, L., Palmer, J. R., Zauber, A. G., et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol (1994), 139:654–61.CrossRefGoogle ScholarPubMed

Hankinson, S. E., Colditz, G. A., Hunter, D. J., et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol (1992), 80:708–14.Google ScholarPubMed

Stanford, J. L.. Oral contraceptives and neoplasia of the ovary. Contraception (1991), 43:543–56.CrossRefGoogle ScholarPubMed

Franceschi, S., Parazzini, F., Negri, E., et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer (1991), 49:61–5.CrossRefGoogle ScholarPubMed

Risch, H. A., Marrett, L. D., Jain, M., et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol (1996), 144:363–72.CrossRefGoogle ScholarPubMed

Rosenblatt, K. A., Thomas, D. B. and Noonan, E. A.. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer (1992), 28A:1872–6.CrossRefGoogle ScholarPubMed

Liang, A. P., Levenson, A. G., Layde, P. M., et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA (1983), 249:2909–12.CrossRefGoogle ScholarPubMed

Modan, B., Hartge, P., Hirsh-Yechezkel, G., et al. National Israel Ovarian Cancer Study Group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001), 345:235–40.CrossRefGoogle ScholarPubMed

Narod, S. A., Risch, H., Moslehi, R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998), 339: 424–8.CrossRefGoogle ScholarPubMed

Whittemore, A. S., Balise, R. R., Pharoah, P. D., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer (2004), 91:1911–5.CrossRefGoogle ScholarPubMed

Mosgaard, B. J., Lidegaard, O., Kjaer, S. K., et al. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril (1998), 70:1049–55.CrossRefGoogle ScholarPubMed

Parazzini, F., Negri, E., Vecchia, C., et al. Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod (1997), 12:2159–61.CrossRefGoogle ScholarPubMed

Dor, J., Lerner-Geva, L., Rabinovici, J., et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril (2002), 77:324–7.CrossRefGoogle Scholar

Doyle, P., Maconochie, N., Beral, V., et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod (2002), 17:2209–13.CrossRefGoogle Scholar

Venn, A., Watson, L., Bruinsma, F., et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet (1999), 354:1586–90.CrossRefGoogle ScholarPubMed

Lacey, J. V. Jr, Mink, P. J., Lubin, J. H., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002), 288:334–41.CrossRefGoogle ScholarPubMed

Rodriguez, C., Patel, A. V., Calle, E. E., et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA (2001), 285:1460–5.CrossRefGoogle Scholar

Riman, T., Dickman, P. W., Nilsson, S., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst (2002), 94: 497–504.CrossRefGoogle ScholarPubMed

Anderson, G. L., Judd, H. L., Kaunitz, A. M., et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003), 290:1739–48.CrossRefGoogle ScholarPubMed

Graham, J. and Graham, R.. Ovarian cancer and asbestos. Environ Res (1967), 1:115–28.CrossRefGoogle ScholarPubMed

Venter, P. F. and Iturralde, M.. Migration of a particulate radioactive tracer from the vagina to the peritoneal cavity and ovaries. S Afr Med J (1979), 55:917–9.Google ScholarPubMed

Cramer, D. W., Liberman, R. F., Titus-Ernstoff, L., et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer (1999), 81:351–6.3.0.CO;2-M>CrossRefGoogle ScholarPubMed

Miracle-McMahill, H. L., Calle, E. E., Kosinski, A. S., et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol (1997), 145:349–57.CrossRefGoogle Scholar

Green, A., Purdie, D., Bain, C., et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer (1997), 71:948–51.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed

Kreiger, N., Sloan, M., Cotterchio, M., et al. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol (1997), 26:710–15.CrossRefGoogle ScholarPubMed

Hankinson, S. E., Hunter, D. J., Colditz, G. A., et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA (1993), 270:2813–18.CrossRefGoogle ScholarPubMed

Ogawa, S., Kaku, T., Amada, S., et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol (2000), 77:298–304.CrossRefGoogle ScholarPubMed

Takahashi, K., Kurioka, H., Irikoma, M., et al. Benign or malignant ovarian neoplasms and ovarian endometriomas. J Am Assoc Gynecol Laparosc (2001), 8:278–84.CrossRefGoogle ScholarPubMed

Schildkraut, J. M., Schwingl, P. J., Bastos, E., et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol (1996), 88:554–9.CrossRefGoogle ScholarPubMed

Balen, A.. Polycystic ovary syndrome and cancer. Hum Reprod Update (2001), 7:522–5.CrossRefGoogle ScholarPubMed

Risch, H. A. and Howe, G. R.. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (1995), 4:447–51.Google ScholarPubMed

Parazzini, F., Vecchia, C., Negri, E., et al. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev (1996), 5:667–9.Google ScholarPubMed

Ness, R. B., Grisso, J. A., Cottreau, C., et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology (2000), 11:111–17.CrossRefGoogle ScholarPubMed

Hisada, M., Berg, B. J., Strickler, H. D., et al. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control (2001), 12:335–41.CrossRefGoogle Scholar

Risch, H. A., Jain, M., Marrett, L. D., et al. Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes Control (1994), 5:540–8.CrossRefGoogle Scholar

Vecchia, C., Decarli, A., Negri, E., et al. Dietary factors and the risk of epithelial ovarian cancer. J Natl Cancer Inst (1987), 79:663–9.

Kushi, L. H., Mink, P. J., Folsom, A. R., et al. Prospective study of diet and ovarian cancer. Am J Epidemiol (1999), 149:21–31.CrossRefGoogle ScholarPubMed

Fairfield, K. M., Hankinson, S. E., Rosner, B. A., et al. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer (2001), 92:2318–26.3.0.CO;2-7>CrossRefGoogle Scholar

Purdie, D. M., Bain, C. J., Webb, P. M., et al. Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control (2001), 12:855–63.CrossRefGoogle Scholar

Kuper, H. D., Cramer, W. and Titus-Ernstoff, L.. Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status?Cancer Causes Control (2002), 13:455–63.CrossRefGoogle ScholarPubMed

Lubin, F., Chetrit, A., Freedman, L. S., et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol (2003), 157:113–20.CrossRefGoogle ScholarPubMed

Lukanova, A., Toniolo, P., Lundin, E., et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer (2002), 99:603–8.CrossRefGoogle ScholarPubMed

Engeland, A., Tretli, S. and Bjorge, T.. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst (2003), 95:1244–8.CrossRefGoogle ScholarPubMed

Fairfield, K. M., Willett, W. C., Rosner, B. A., et al. Obesity, weight gain, and ovarian cancer. Obstet Gynecol (2002), 100:288–96.Google ScholarPubMed